Why the study?
Does monotherapy with perindopril, eprosartan, or amlodipine improve cognitive function in patients with arterial hypertension and obesity?
Does monotherapy with perindopril, eprosartan, or amlodipine improve cognitive function in patients with arterial hypertension and obesity?
Eprosartan and amlodipine monotherapy for 12 months significantly improved cognitive function in patients with hypertension and obesity.
Answers are grounded in this paper and cite their sources.
May support cognitive monitoring in obese hypertensives on these agents; leaves open confirmation in larger randomized trials.
Objective. To assess and compare efficacy of perindopril, eprosartan and amlodipine according to their effects on cognitive function in patients with arterial hypertension and obesity. Design and methods. This open clinical trial included 78 patients (mean age — 46,8 ± 5,5 years), 26 of them received perindopril, 26 — eprosartan, and 26 — amlodipine. Monotherapy has lasted for 12 months. At baseline and 12 months later, all participants underwent 24-hour blood pressure monitoring, neuropsychological testing and cognitive evoked potential (P300) to assess cognitive function. Results. Twelve-month monotherapy with eprosartan and amlodipine significantly improved cognitive function (neuropsychological testing and P300) in patients with obesity and arterial hypertension.
No takes yet. Share an insight, caveat, or question.
Зуева et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: